Market News

Abbott Delivers Better-than-Expected Q4 Earnings

Shares of Abbott Labs (NYSE: ABT) fell in pre-market trading on Wednesday even as the medical devices and healthcare company reported better-than-expected Q4 earnings. The company’s adjusted Q4 earnings came in at $1.03 per share, which beat analysts’ consensus estimate of $0.93.

Sales declined by 12%% year-over-year as a result of a drop in sales of COVID-19 testing kits, with revenue hitting $10.1 billion in the fourth quarter. However, this still beat analysts’ expectations by $410 million.

Looking forward, management now expects organic sales to be around $2 billion in FY23 while adjusted earnings are expected to come in the range of $4.30 to $4.50 per share.

Overall, Wall Street analysts are upbeat about ABT stock with a Strong Buy consensus rating based on five Buys and one Hold.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More